Display options
Cite
Weiss BD, Yanik G, Naranjo A, et al. A safety and feasibility trial of . Pediatr Blood Cancer. 2021;68(10):e29117doi: 10.1002/pbc.29117.
Weiss, B. D., Yanik, G., Naranjo, A., Zhang, F. F., Fitzgerald, W., Shulkin, B. L., Parisi, M. T., Russell, H., Grupp, S., Pater, L., Mattei, P., Mosse, Y., Lai, H. A., Jarzembowski, J. A., Shimada, H., Villablanca, J. G., Giller, R., Bagatell, R., Park, J. R., & Matthay, K. K. (2021). A safety and feasibility trial of . Pediatric blood & cancer, 68(10), e29117. https://doi.org/10.1002/pbc.29117
Weiss, Brian D, et al. "A safety and feasibility trial of ." Pediatric blood & cancer vol. 68,10 (2021): e29117. doi: https://doi.org/10.1002/pbc.29117
Weiss BD, Yanik G, Naranjo A, Zhang FF, Fitzgerald W, Shulkin BL, Parisi MT, Russell H, Grupp S, Pater L, Mattei P, Mosse Y, Lai HA, Jarzembowski JA, Shimada H, Villablanca JG, Giller R, Bagatell R, Park JR, Matthay KK. A safety and feasibility trial of . Pediatr Blood Cancer. 2021 Oct;68(10):e29117. doi: 10.1002/pbc.29117. Epub 2021 May 24. PMID: 34028986.
Copy Download .nbib Format: NLM
Share it on

Pediatr Blood Cancer. 2021 Oct;68(10):e29117. doi: 10.1002/pbc.29117. Epub 2021 May 24.

A safety and feasibility trial of .

Pediatric blood & cancer

Brian D Weiss, Gregory Yanik, Arlene Naranjo, Fan F Zhang, Wendy Fitzgerald, Barry L Shulkin, Marguerite T Parisi, Heidi Russell, Stephan Grupp, Luke Pater, Peter Mattei, Yael Mosse, Hollie A Lai, Jason A Jarzembowski, Hiroyuki Shimada, Judith G Villablanca, Roger Giller, Rochelle Bagatell, Julie R Park, Katherine K Matthay

Affiliations

  1. Cincinnati Children's Hospital, University of Cincinnati School of Medicine Cincinnati, Ohio.
  2. CS Mott Children's Hospital, University of Michigan School of Medicine, Ann Arbor, Michigan.
  3. Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, Florida.
  4. Children's Oncology Group Statistics and Data Center, Monrovia, California.
  5. Children's National Health System, District of Columbia, Washington.
  6. St. Jude Children's Research Hospital, University of Tennessee Health Science Center, Memphis, Tennessee.
  7. Seattle Children's Hospital, Seattle, Washington.
  8. Texas Children's Cancer and Hematology Centers, Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas.
  9. Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  10. Children's Hospital of Orange County, Orange, California.
  11. Midwest Children's Cancer Center, Milwaukee, Wisconsin.
  12. Lucille Packards Children's Hospital, Palo Alto, California.
  13. Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.
  14. Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.
  15. Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington.
  16. UCSF Benioff Children's Hospital, University of California San Francisco School of Medicine, San Francisco, California.

PMID: 34028986 DOI: 10.1002/pbc.29117

Abstract

METHODS: Patients with MIBG-avid high-risk neuroblastoma were eligible. After the first two patients to receive protocol therapy developed severe sinusoidal obstruction syndrome (SOS), the trial was re-designed to include an

RESULTS: Fifty-nine of 68 patients (86.8%) who completed induction chemotherapy received

CONCLUSION: This pilot trial demonstrated feasibility and tolerability of administering

© 2021 Wiley Periodicals LLC.

Keywords: Bu/Mel; MIBG; high risk; neuroblastoma

References

  1. Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322(8):746-755. - PubMed
  2. Pinto N, Naranjo A, Hibbitts E, et al. Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children's Oncology Group (COG). Eur J Cancer. 2019;112:66-79. - PubMed
  3. Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14(10):999-1008. - PubMed
  4. Ladenstein R, Potschger U, Pearson ADJ, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18(4):500-514. - PubMed
  5. Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013;54(4):541-548. - PubMed
  6. Ladenstein R, Lambert B, Potschger U, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018;45(2):292-305. - PubMed
  7. Matthay KK, Harris R, Reynolds CP, et al. Improved event-free survival (EFS) for autologous bone marrow transplantation (ABMT) vs chemotherapy in neuroblastoma: a phase III randomized Children's Cancer Group (CCG) study. Proc Am Soc Clin Oncol. 1998;17:525a. - PubMed
  8. Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur J Cancer. 2015;51(16):2465-2472. - PubMed
  9. DuBois SG, Matthay KK. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. Q J Nucl Med Mol Imaging. 2013;57(1):53-65. - PubMed
  10. De Kraker J, Hoefnagel CA, Caron H, et al. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer. 1995;4(4):600-602. - PubMed
  11. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, HN Caron. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer. 2008;44(4):551-556. - PubMed
  12. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25(9):1054-1060. - PubMed
  13. Mastrangelo S, Rufini V, Ruggiero A, Di Giannatale A, Riccardi R. Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of (1)(3)(1)I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen. Pediatr Blood Cancer. 2011;56(7):1032-1040. - PubMed
  14. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm. 2005;20(2):195-199. - PubMed
  15. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20(8):2142-2149. - PubMed
  16. Klingebiel T, Bader P, Bares R, et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy: a pilot study. Eur J Cancer. 1998;34(9):1398-1402. - PubMed
  17. Giardino S, Piccardo A, Conte M, et al. 131) I-Meta-iodobenzylguanidine followed by busulfan and melphalan and autologous stem cell rescue in high-risk neuroblastoma. Pediatr Blood Cancer. 2020:e28775. - PubMed
  18. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006;24(3):500-506. - PubMed
  19. Yanik GA, Villablanca JG, Maris JM, et al. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: a New Approaches to Neuroblastoma Therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015;21(4):673-681. - PubMed
  20. Miano M, Garaventa A, Pizzitola MR, et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant. 2001;27(6):571-574. - PubMed
  21. French S, DuBois SG, Horn B, et al. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2013;60(5):879-884. - PubMed
  22. Ferry I, Kolesnikov-Gauthier H, Oudoux A, et al. Feasibility of busulfan melphalan and stem cell rescue after 131I-MIBG and topotecan therapy for refractory or relapsed metastatic neuroblastoma: the French experience. J Pediatr Hematol Oncol. 2018;40(6):426-432. - PubMed
  23. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86(2):349-363. - PubMed
  24. DuBois SG, Allen S, Bent M, et al. Phase I/II study of I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer. 2015;112(4):644-649. - PubMed
  25. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466-1477. - PubMed
  26. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-1334. - PubMed
  27. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med. 2001;42(11):1713-1721. - PubMed
  28. Messina JA, Cheng SC, Franc BL, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006;47(7):865-874. - PubMed
  29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53(282):457-481. - PubMed
  30. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977;35(1):1-39. - PubMed
  31. Genolla J, Rodriguez T, Minguez P, Lopez-Almaraz R, Llorens V, Echebarria A. Dosimetry-based high-activity therapy with (131)I-metaiodobenzylguanidine ((131)I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma. Eur J Nucl Med Mol Imaging. 2019;46(7):1567-1575. - PubMed
  32. Kraal KC, Tytgat GA, van Eck-Smit BL, Kam B, Caron HN, van Noesel M. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan. Pediatr Blood Cancer. 2015;62(11):1886-1891. - PubMed
  33. Bilodeau M, Ma C, Al-Sayegh H, Wolfe J, Bona K. Household material hardship in families of children post-chemotherapy. Pediatr Blood Cancer. 2018;65(1):10.1002/pbc.26743. - PubMed
  34. Tucker-Seeley RD, Abel GA, Uno H, Prigerson H. Financial hardship and the intensity of medical care received near death. Psychooncology. 2015;24(5):572-578. - PubMed
  35. Fluchel MN, Kirchhoff AC, Bodson J, et al. Geography and the burden of care in pediatric cancers. Pediatr Blood Cancer. 2014;61(11):1918-1924. - PubMed
  36. Matthay K, Yanik G, Maris J, et al. 131I-MIBG with myeloablative chemotherapy and autologous stem cell transplant in refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy (NANT) consortium study. Med Pediatr Oncol. 2002. In press. - PubMed
  37. Desai AV, Heneghan MB, Li Y, et al. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma. Bone Marrow Transplant. 2016;51(9):1204-1210. - PubMed

Publication Types